UAB spin-off's tech could shorten drug dev to 6 weeks

Findings from research at the University of Alabama at Birmingham has helped create a company--Soluble Therapeutics--that specializes in protein-based drugs and vaccines. The spin-off has created technology that speeds the production of protein-based products used in insulin production and blood clot treatments. Drug development that used to take 12 to 18 months could be shortened to as little as six weeks with the new technology, CEO Joseph Garner explains.

The company has orders to fill for the remainder of the year and has been looking to expand, Garner says. "We hope in the next couple of months to be adding to the work force as there is gained interest in this form of technology," he adds.

Soluble is the second biotechnology company to spin off from UAB research and incorporate this year, the other being VIPAAR, the Birmingham Business Journal reports. In addition, it is one of about 40 entities to spin off from the school's R&D since the UAB Research Foundation formed more than 20 years ago, according to the foundation's website.

- get more from the Birmingham Business Journal

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.